Shilpa Medicare Ltd (SHILPAMED) Q1 FY27 Results Analysis: Revenue Surges 44.89%, EBITDA Margin Expands 226 bps

Shilpa Medicare Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 465.78 Cr (+44.89% YoY) and PAT growth of +115.19% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Revenue grew 44.89% YoY with EBITDA margin expanding 226 bps, driven by operating leverage and cost management. PAT more than doubled, though a one-time deferred tax reversal inflated reported earnings. The strong operational momentum is positive, but the employee cost spike and absence of explicit guidance limit conviction.

Key Investment Insights

Key Positives

• Revenue grew 44.89% YoY to Rs.465.78 Cr, the highest Q1 print in the visible trajectory.
• EBITDA margin expanded 226 bps YoY to 30.54%, reflecting operating leverage as costs grew slower than revenue.
• PAT grew 115.19% YoY to Rs.100.88 Cr; normalized PAT of Rs.74.04 Cr still grew 57.9% YoY.
• Finance costs fell 35.57% YoY to Rs.12.10 Cr, a significant positive surprise versus the expected headwind.
• Cost of materials consumed grew only 25.64% YoY, much slower than revenue, indicating favorable product mix.

Risk Factors

• Employee benefits expense jumped 15.19% QoQ to Rs.99.71 Cr, which needs monitoring if it persists.
• Reported PAT was inflated by a one-time deferred tax reversal of Rs.26.84 Cr; normalized PAT is Rs.74.04 Cr.
• The company received a Form 483 with 5 observations at Unit VI, though VAI status is maintained.
• The STPL merger creates comparability noise for YoY analysis, as standalone revenue doubled partly due to the merger.